Reply to Piehler : Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy.
作者信息
Duff Alistair J A, Lee Tim W R
机构信息
Leeds Centre for Children's Respiratory Medicine and.
Department of Paediatric Psychology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
出版信息
Am J Respir Crit Care Med. 2024 Aug 1;210(3):367. doi: 10.1164/rccm.202404-0852LE.
Abstract
摘要
相似文献
1
Reply to Piehler : Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy.
Am J Respir Crit Care Med. 2024 Aug 1;210(3):367. doi: 10.1164/rccm.202404-0852LE.
2
Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy.
Am J Respir Crit Care Med. 2024 Aug 1;210(3):365-367. doi: 10.1164/rccm.202404-0787LE.
3
Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
J Cyst Fibros. 2024 Mar;23(2):366-367. doi: 10.1016/j.jcf.2023.10.008. Epub 2023 Oct 13.
4
Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
Eur Respir J. 2024 Sep 26;64(3). doi: 10.1183/13993003.01247-2024. Print 2024 Sep.
5
Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
Eur Respir J. 2024 Sep 26;64(3). doi: 10.1183/13993003.00929-2024. Print 2024 Sep.
6
Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.
Arch Bronconeumol. 2024 Aug;60(8):526-528. doi: 10.1016/j.arbres.2024.04.007. Epub 2024 Apr 24.
7
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.
Pediatr Pulmonol. 2024 Jul;59(7):2009-2011. doi: 10.1002/ppul.26997. Epub 2024 Apr 12.
8
Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant.
J Cyst Fibros. 2024 May;23(3):561-562. doi: 10.1016/j.jcf.2023.11.004. Epub 2023 Nov 24.
9
Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor.
Pediatr Pulmonol. 2024 Jul;59(7):2051-2054. doi: 10.1002/ppul.27018. Epub 2024 Apr 17.
10
Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
Clin Pharmacol Ther. 2024 Jun;115(6):1204-1207. doi: 10.1002/cpt.3214. Epub 2024 Feb 22.
本文引用的文献
1
Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis.
Am J Respir Crit Care Med. 2024 Feb 1;209(3):239-241. doi: 10.1164/rccm.202311-2159ED.
2
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Am J Respir Crit Care Med. 2024 Feb 1;209(3):299-306. doi: 10.1164/rccm.202308-1525OC.
3
Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis.
Front Pharmacol. 2023 Apr 21;14:1179208. doi: 10.3389/fphar.2023.1179208. eCollection 2023.
Zotero 插件